Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Encenicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 15/20 | 1.00 |
| ▸ | HTR3A | P46098 | 5/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.69 |
| ▸ | HTR3B | O95264 | 1/20 | 0.69 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.69 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Encenicline SCHEMBL743562 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL6633208 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL744202 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL12971448 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL2893312 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL29464033 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL12971447 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL744203 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL746834 | 0.98 | CHRNA7 (0.96) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Encenicline SCHEMBL746833 | 0.98 | CHRNA7 (0.96) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | claimed |
| EP-3666272-A1 | USE OF ENCENICLINE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, MEMORY DEFICIT | Forum Pharmaceuticals Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| EP-3357495-B1 | TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AXOVANT SCIENCES GMBH (CH) | 2019-12-25 | — | — | EP | claimed |
| EP-3461481-A1 | METHODS OF MAINTAINING, TREATING OR IMPROVING COGNITIVE FUNCTION | Forum Pharmaceuticals Inc. (US) | 2019-04-03 | — | — | EP | claimed |
| US-20180271844-A1 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof | FORUM PHARMACEUTICALS INC (US) | 2018-09-27 | — | — | US | claimed |
| WO-2018152554-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. (US) | 2018-08-23 | — | — | WO | claimed |
| EP-3357495-A1 | TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Forum Pharmaceuticals Inc. (US) | 2018-08-08 | — | — | EP | claimed |
| US-20180214431-A1 | Methods of Maintaining, Treating or Improving Cognitive Function | FORUM PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | claimed |
| EP-2889033-B1 | Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | FORUM PHARMACEUTICALS INC (US) | 2018-03-21 | — | — | EP | claimed |
| EP-3029039-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING CRYSTALLINE FORMS OF (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO(B)THIOPHENE-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE | FORUM PHARMACEUTICALS INC (US) | 2017-08-23 | — | — | EP | claimed |
| EP-2429518-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTORS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | Envivo Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2011156802-A1 | TOPICAL SKIN CREAM COMPRISING PHOSPHATIDYCHOLINE DHA AND L-TYROSINE | PERRICONE, NICOLAS, V. (US) | 2011-12-15 | — | — | WO | claimed |
| US-8076355-B2 | 2-heteroarylcarboxylic acid amides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-13 | — | — | US | claimed |
| US-20110288119-A1 | Low dose - prov (alpha 7-EVP) | FMR LLC | 2011-11-24 | — | — | US | claimed |
| EP-2355822-A1 | TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZOÝB¨THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Envivo Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| US-20110124631-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTORS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | FORUM PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | claimed |
| WO-2010132423-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTORS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | claimed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | claimed |
| WO-2010059844-A1 | TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNA7 1/4885HTR3A 151/4885HTR3E 425/4885 |
| US-20110124631-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTORS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | CHRNA7 1/4885HTR3A 354/4885HTR3E 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.